Discovery and Structure−Activity Relationship of Antagonists of B-Cell Lymphoma 2 Family Proteins with Chemopotentiation Activity in Vitro and in Vivo
journal contributionposted on 09.02.2006, 00:00 by Michael D. Wendt, Wang Shen, Aaron Kunzer, William J. McClellan, Milan Bruncko, Thorsten K. Oost, Hong Ding, Mary K. Joseph, Haichao Zhang, Paul M. Nimmer, Shi-Chung Ng, Alexander R. Shoemaker, Andrew M. Petros, Anatol Oleksijew, Kennan Marsh, Joy Bauch, Tilman Oltersdorf, Barbara A. Belli, Darlene Martineau, Stephen W. Fesik, Saul H. Rosenberg, Steven W. Elmore
Development of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bcl-XL function, is described. Lead compounds generated by NMR screening and directed parallel synthesis displayed sub-μM binding but were strongly deactivated in the presence of serum. The dominant component of serum deactivation was identified as domain III of human serum albumin (HSA); NMR solution structures of inhibitors bound to both Bcl-XL and HSA domain III indicated two potential optimization sites for separation of affinities. Modifications at both sites resulted in compounds with improved Bcl-XL binding and greatly increased activity in the presence of human serum, culminating in 73R, which bound to Bcl-XL with a Ki of 0.8 nM. In a cellular assay 73R reversed the protection afforded by Bcl-XL overexpression against cytokine deprivation in FL5.12 cells with an EC50 of 0.47 μM. 73R showed little effect on the viability of the human non small cell lung cancer cell line A549. However, consistent with the proposed mechanism, 73R potentiated the activity of paclitaxel and UV irradiation in vitro and potentiated the antitumor efficacy of paclitaxel in a mouse xenograft model.